QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Immatics N.V. (IMTX)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
2

Do Nothing: technicalScore 2 (below the required 3) — price 6.39 is below the SMA20 6.97, SMA50 7.71, SMA200 9.43, EMA9/21 and WMA9/21 after printing a new 52-week low 6.085 on 11/13, with MACD histogram -0.01 and ADX 24.87 pointing down; the only contender, a pullback/oversold limit, is blocked as countertrend (price < SMA50 with macdLine -0.36 < 0, and price < a declining SMA200 with no reclaim), and no breakout stop qualifies because a trigger above the settled 6.545 high would fill into the EMA21 6.92 / SMA20 6.97 resistance band off a one-day oversold bounce rather than a base.

Analysis as of 2026-11-13· more than 2 trading days ago

Company overview

Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing T-cell receptor-based immunotherapies for cancer treatment, primarily in the U.S. Its approach includes adoptive cell therapies and TCR Bispecifics targeting solid tumors. The company collaborates with partners like GlaxoSmithKline and MD Anderson Cancer Center to advance its pipeline.

Fundamental

fair
Fundamental3
Mixed fundamentals

Immatics shows strong liquidity but faces deepening losses and reliance on future clinical outcomes.

Mixed fundamentals with elevated clinical risk: a clinical-stage TCR immunotherapy company with a fortress balance sheet (roughly half a billion euros pro-forma after the August 2026 raise, negligible lease-only debt, clean audit, no going-concern) offset by deep and widening losses (€196.4M net loss in FY2025), negative operating cash flow, declining lumpy collaboration revenue, and frequent dilutive equity raises. The recurring earnings run-rate is loss-making - the FY2022/FY2024 profit years were one-time collaboration artifacts. Near-term value hinges on the SUPRAME Phase 3 melanoma readout expected in 1H 2027; consensus analyst target of $17 implies meaningful upside and Perceptive Advisors recently added shares at $8.69. Speculative with a defined catalyst; not distressed.

Sentiment

fair
Sentiment3
Neutral sentiment

Media and retail interest are mild, with insider buying providing some positive sentiment.

The $150M underwritten offering (announced Aug 25, completed Aug 26) is a fresh bearish supply overhang the tape has only partly absorbed — shares sit ~9% above the $8.69 offer price — offset by Perceptive Advisors' 863K-share open-market buy at that same $8.69 anchor, a media-covered insider conviction leg the market rewarded; the sentiment delta is determinate but flat (+0.14 baseline vs +0.07 scoring), retail velocity is indeterminate, the legal screen is clean, and moderate red-flag caps apply (opportunistic dilution on a healthy balance sheet; conflicting bearish/bullish signals in the same actionable window).

Technical

weak
Technical2
Weak technicals

The stock is in a downtrend, trading below key moving averages with no clear reversal signals.

IMTX is a broken downtrend, not a base: price 6.39 sits below the SMA20 6.97, SMA50 7.71 and SMA200 9.43, the EMA9 6.60 and EMA21 6.92, the WMA9 6.49 and WMA21 6.78, and above only the DEMA14 6.40/TEMA14 6.38 by a cent — the moving-average stack is fully bearish and the 50-day sits below the 200-day. The daily sequence is a textbook run of lower highs (7.52 on 11/04 → 7.00 on 11/05 → 6.89 on 11/12 → 6.545 on 11/13) and lower lows, with today's 11/13 session printing a new 52-week low at 6.085 before reversing to close at 6.39 (+4.9% off the low). Momentum is weak but far from washed out: RSI14 36.06, Williams %R -78.75, MACD line -0.36 below its -0.35 signal with the histogram still negative at -0.01 (improving from -0.05 on 11/09 but no bullish crossover), and ADX14 24.87 — high enough to confirm a directional trend, and with price under every average that direction is down, even as the ADX decays from 29.2 (decelerating, not reversing). The lone constructive feature is the marginal double-bottom test (11/06 low 6.09 vs 11/13 low 6.085) with a positive intraday reversal and a close above the 6.34 session VWAP; that supports at best a bounce-only trade, and a bounce-only chart does not clear the technicalScore >= 3 entry bar. Score 2: mostly weak bearish, bounce-only.

You’re looking at 2026-11-13 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.